Quantcast

Latest Daunorubicin Stories

2009-01-23 09:41:54

Researchers at the Johns Hopkins University School of Medicine have discovered how a whole class of commonly used chemotherapy drugs can block cancer growth. Their findings, reported online this week at the Proceedings of the National Academy of Sciences Early Edition, suggest that a subgroup of cancer patients might particularly benefit from these drugs.The anthracycline class of chemotherapeutics "” doxorubicin (Adriamycin), daunorubicin, epirubicin, idarubicin "” have been used...

2009-01-22 07:00:00

WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML). Through the partnership, LLS will provide $3.7 million to support Celator's Phase 2B multicenter, randomized, open-label trial of CPX-351 versus...

2009-01-08 11:38:00

PRINCETON, N.J., Jan. 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Biotech Showcase 2009 in San Francisco. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentation will be held on Wednesday, January 14, 2009 at 10:30AM PST in Room A of the Marines' Memorial Club & Hotel. About Celator Celator(R) Pharmaceuticals, Inc., with...

2008-12-09 07:00:00

Findings confirm advantages of fixed-ratio drug delivery and lay the groundwork for Phase 2 trials already underway in first-line and first-relapse Acute Myeloid Leukemia (AML) settings PRINCETON, N.J., Dec. 9 /PRNewswire/ -- Celator Pharmaceuticals today announced that a Phase 1 dose escalating study of CPX-351 (cytarabine:daunorubicin) Liposome Injection established the recommended dose for Phase 2 studies and confirmed preliminary observations of safety, enhanced pharmacokinetics and...

2008-09-23 12:00:52

Vion Pharmaceuticals, which develops and commercializes cancer therapeutics, has signed an agreement with the Institut Paoli-Calmettes in Marseille, France to conduct a multi-center Phase I/II clinical trial of laromustine with remission-induction therapy in patients aged 18-60 with previously untreated acute myelogenous leukemia and a poor prognosis based on their cytogenetic profile. The trial will be conducted in two parts. In Phase I, the objective will be to determine the dose of...

2008-09-05 03:00:27

Celator Pharmaceuticals has announced that the FDA has granted orphan drug designation to CPX-351 liposome injection for the treatment of acute myeloid leukemia. Celator is currently preparing to conduct two randomized Phase II studies with CPX-351. The first Phase II study, in newly diagnosed, elderly patients with acute myeloid leukemia (AML) is expected to start enrolling patients before the end of 2008. The second study, in AML patients who have relapsed following initial treatment,...

2008-07-29 12:01:25

Celator Pharmaceuticals, which develops novel products based on proven combinations of chemotherapeutic drugs, has raised in excess of $22.5 million in a series C private equity financing. All series B investors participated in the financing and included; Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital. The proceeds will be used to fund Phase II studies of CPX-351, a liposomal formulation of cytarabine: daunorubicin in patients with...

2008-07-28 18:00:42

PRINCETON, N.J., July 28 /PRNewswire-FirstCall/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing novel products based on proven combinations of chemotherapeutic drugs, today announced that it raised in excess of $22.5 million in a Series C private equity financing. All Series B investors participated in the financing and included; Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital, and BDC Capital. The proceeds will be...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related